Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 23, 2009

Intercytex Wind-Down Continues with Sale of Stem Cell Therapies Assets to Pfizer for $750,000

  • Intercytex has sold part of its stem cell therapeutics subsidiary, Axordia, to Pfizer for $750,000 in cash,  £75,000 ($124,613) of the total payment will be held in escrow until 2010. The company has also closed its offices in the U.K. and U.S., and is now being run by its three executive directors, who are also on notice.

    Intercytex started to implement cash-saving measures in January 2009, less than a month before the company announced that its lead venous leg ulcers product candidate, Cyzact®, failed in Phase III trials. Since then the company has been looking for a merger option or to sell off its assets piecemeal. Intercytex shares stopped trading on the U.K.’s Alternative Investment Market in September.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »